title: Growth deceleration in children treated with imatinib   for chronic myeloid leukaemia.
abstract: OBJECTIVE
  The aim is to study statural growth in a large cohort of children with chronic myeloid leukaemia (CML) treated with front-line imatinib.
  
  
  METHODS
  Retrospective data from 81 children less than 18 years of age with CML identified in the French pediatric registry were analysed. Height was expressed as standard deviation score (SDS).
  
  
  RESULTS
  A gradual decrease in height SDS was observed over time since starting imatinib. The height SDS was significantly lower 12 months and 24 months after the start of imatinib overall (p < 10(-4)) irrespective of gender and pubertal age. The height SDS was significantly (p < 10(-4)) lower 12 months after the start of imatinib in boys and girls, and in the prepubertal age group as well as in the postpubertal age group, respectively. A similar finding was observed in the subgroups of boys and girls starting imatinib at a prepubertal or postpubertal age. Loss in height SDS 12 months after the start of imatinib was of the same range in boys when compared to girls and in patients who started imatinib at a prepubertal age compared to those who started at a postpubertal age.
  
  
  CONCLUSIONS
  Growth velocity was altered during the first years of imatinib treatment in boys as well as in girls and in prepubertal age patients as well as in adolescents.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Millot
authors.forename: Joelle
authors.initials: J
authors.lastname: Guilhot
authors.forename: André
authors.initials: A
authors.lastname: Baruchel
authors.forename: Arnaud
authors.initials: A
authors.lastname: Petit
authors.forename: Thierry
authors.initials: T
authors.lastname: Leblanc
authors.forename: Yves
authors.initials: Y
authors.lastname: Bertrand
authors.forename: Françoise
authors.initials: F
authors.lastname: Mazingue
authors.forename: Patrick
authors.initials: P
authors.lastname: Lutz
authors.forename: Cecile
authors.initials: C
authors.lastname: Vérité
authors.forename: Christian
authors.initials: C
authors.lastname: Berthou
authors.forename: Claire
authors.initials: C
authors.lastname: Galambrun
authors.lastname: Nicolas Sirvent
authors.forename: Karima
authors.initials: K
authors.lastname: Yacouben
authors.forename: Pascal
authors.initials: P
authors.lastname: Chastagner
authors.forename: Virginie
authors.initials: V
authors.lastname: Gandemer
authors.forename: Yves
authors.initials: Y
authors.lastname: Reguerre
authors.forename: Gérard
authors.initials: G
authors.lastname: Couillault
authors.forename: Tackwa
authors.initials: T
authors.lastname: Khalifeh
authors.forename: Fanny
authors.initials: F
authors.lastname: Rialland
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides / Q000009:adverse effects*; D001827:Body Height / Q000187:drug effects; D015992:Body Mass Index; D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000139:chemically induced*; D006801:Humans; D000068877:Imatinib Mesylate; D007223:Infant; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate